167 related articles for article (PubMed ID: 37592236)
1. The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice.
Gu Y; Avolio E; Alvino VV; Thomas AC; Herman A; Miller PJ; Sullivan N; Faulkner A; Madeddu P
Cardiovasc Diabetol; 2023 Aug; 22(1):214. PubMed ID: 37592236
[TBL] [Abstract][Full Text] [Related]
2. Impact of Syndecan-2-Selected Mesenchymal Stromal Cells on the Early Onset of Diabetic Cardiomyopathy in Diabetic db/db Mice.
Pappritz K; Dong F; Miteva K; Kovacs A; El-Shafeey M; Kerim B; O'Flynn L; Elliman SJ; O'Brien T; Hamdani N; Tschöpe C; Van Linthout S
Front Cardiovasc Med; 2021; 8():632728. PubMed ID: 34095245
[No Abstract] [Full Text] [Related]
3. Cellular Senescence in Diabetes Mellitus: Distinct Senotherapeutic Strategies for Adipose Tissue and Pancreatic β Cells.
Murakami T; Inagaki N; Kondoh H
Front Endocrinol (Lausanne); 2022; 13():869414. PubMed ID: 35432205
[TBL] [Abstract][Full Text] [Related]
4. The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells.
Borriello A; Caldarelli I; Basile MA; Bencivenga D; Tramontano A; Perrotta S; Della Ragione F; Oliva A
PLoS One; 2011; 6(12):e28555. PubMed ID: 22164306
[TBL] [Abstract][Full Text] [Related]
5. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.
Mokhtari D; Welsh N
Clin Sci (Lond); 2009 Nov; 118(4):241-7. PubMed ID: 19886867
[TBL] [Abstract][Full Text] [Related]
6. Blackcurrant Improves Diabetic Cardiovascular Dysfunction by Reducing Inflammatory Cytokines in Type 2 Diabetes Mellitus Mice.
Kim HY; Yoon JJ; Lee HK; Tai AL; Lee YJ; Kim DS; Kang DG; Lee HS
Nutrients; 2021 Nov; 13(11):. PubMed ID: 34836432
[TBL] [Abstract][Full Text] [Related]
7. Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes.
Huynh K; Kiriazis H; Du XJ; Love JE; Jandeleit-Dahm KA; Forbes JM; McMullen JR; Ritchie RH
Diabetologia; 2012 May; 55(5):1544-53. PubMed ID: 22374176
[TBL] [Abstract][Full Text] [Related]
8. Comparison of therapeutic effects of mesenchymal stem cells from umbilical cord and bone marrow in the treatment of type 1 diabetes.
Zhang W; Ling Q; Wang B; Wang K; Pang J; Lu J; Bi Y; Zhu D
Stem Cell Res Ther; 2022 Aug; 13(1):406. PubMed ID: 35941696
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib, a selective tyrosine kinase inhibitor, prevents joint destruction in rheumatoid arthritis animal model.
Min HK; Kim SH; Won JY; Kim KW; Lee JY; Lee SH; Kim HR
Int J Rheum Dis; 2023 Apr; 26(4):718-726. PubMed ID: 36808837
[TBL] [Abstract][Full Text] [Related]
10. Glycemic control by umbilical cord-derived mesenchymal stem cells promotes effects of fasting-mimicking diet on type 2 diabetic mice.
Zhao N; Gao YF; Bao L; Lei J; An HX; Pu FX; Cheng RP; Chen J; Ni H; Sui BD; Ji FP; Hu CH
Stem Cell Res Ther; 2021 Jul; 12(1):395. PubMed ID: 34256832
[TBL] [Abstract][Full Text] [Related]
11. Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice.
Fukuda M; Nakamura T; Kataoka K; Nako H; Tokutomi Y; Dong YF; Yasuda O; Ogawa H; Kim-Mitsuyama S
J Pharmacol Exp Ther; 2010 Oct; 335(1):70-5. PubMed ID: 20651026
[TBL] [Abstract][Full Text] [Related]
12. The PKD inhibitor CID755673 enhances cardiac function in diabetic db/db mice.
Venardos K; De Jong KA; Elkamie M; Connor T; McGee SL
PLoS One; 2015; 10(3):e0120934. PubMed ID: 25798941
[TBL] [Abstract][Full Text] [Related]
13. Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db/db mice.
Pham TK; Nguyen THT; Yi JM; Kim GS; Yun HR; Kim HK; Won JC
Exp Mol Med; 2023 Apr; 55(4):767-778. PubMed ID: 37009790
[TBL] [Abstract][Full Text] [Related]
14. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice.
Everard A; Matamoros S; Geurts L; Delzenne NM; Cani PD
mBio; 2014 Jun; 5(3):e01011-14. PubMed ID: 24917595
[TBL] [Abstract][Full Text] [Related]
15. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
[TBL] [Abstract][Full Text] [Related]
16. Targeting senescence improves angiogenic potential of adipose-derived mesenchymal stem cells in patients with preeclampsia.
Suvakov S; Cubro H; White WM; Butler Tobah YS; Weissgerber TL; Jordan KL; Zhu XY; Woollard JR; Chebib FT; Milic NM; Grande JP; Xu M; Tchkonia T; Kirkland JL; Lerman LO; Garovic VD
Biol Sex Differ; 2019 Sep; 10(1):49. PubMed ID: 31521202
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
[TBL] [Abstract][Full Text] [Related]
18. Liver X receptor agonist treatment attenuates cardiac dysfunction in type 2 diabetic db/db mice.
He Q; Pu J; Yuan A; Yao T; Ying X; Zhao Y; Xu L; Tong H; He B
Cardiovasc Diabetol; 2014 Nov; 13():149. PubMed ID: 25416469
[TBL] [Abstract][Full Text] [Related]
19. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
Trivedi D; Landsman-Blumberg P; Darkow T; Smith D; McMorrow D; Mullins CD
J Manag Care Spec Pharm; 2014 Oct; 20(10):1006-15. PubMed ID: 25278323
[TBL] [Abstract][Full Text] [Related]
20. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
Lin B; Koibuchi N; Hasegawa Y; Sueta D; Toyama K; Uekawa K; Ma M; Nakagawa T; Kusaka H; Kim-Mitsuyama S
Cardiovasc Diabetol; 2014 Oct; 13():148. PubMed ID: 25344694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
